Bill Gates mentions accelerated rollout of HIV cur

Bill Gates mentions accelerated rollout of HIV cure

For those who haven't been following closely, CYDY recently added HIV expert Dr. Max Lataillade as "Senior Vice President and Head of Clinical Development". Details here:
https://www.cytodyn.com/newsroom/press-releas...enior-vice

On the very same day that Dr. Max updated his Linkedin page by adding his new role at CYDY, Dr. Max also announced his new role as "Head of HIV Drug Development Bill & Melinda Gates Foundation". Details here:
https://www.linkedin.com/in/maxlataillade/

This is worth reading (key excerpt: "This led the researchers to determine that stopping HIV from using the CCR5 receptor to infect donor cells is also needed for a cure to occur."
https://news.ohsu.edu/2023/05/25/ohsu-researc...-in-people

Also worth reading:
https://www.biospace.com/cytodyn-highlights-n...leronlimab

And:
https://www.cytodyn.com/newsroom/press-releas...eronlimabs

Now check out this (new) two-minute video interview where Bill Gates talks about the Gates foundation currently developing a cure for HIV and the possibility of rolling it out at an accelerated pace:

https://www.wsj.com/politics/policy/bill-gate...g-e54fc20d

Hopefully CYDY's Leronlimab will play a major role in the HIV Cure that the Gates foundation is developing and planning to rollout in the near future. In addition to saving countless lives, this is noteworthy (per ChatGPT): "According to recent market reports, the global HIV drugs market is currently valued at around $33 billion and is expected to reach approximately $49.68 billion by 2032, growing at a CAGR of 4.3% with combination-class drugs dominating the market share; this indicates a substantial market for HIV treatments, although a true "cure" is not yet widely available."

Excerpted from CYDY's website:
"...Leronlimab is being studied for HIV... Leronlimab is a competitive rather than allosteric inhibitor of the CCR5 receptor. We believe this mechanism of action, of binding competitively to the CCR5 receptor, differentiates leronlimab from all other CCR5 antagonists."

"Leronlimab belongs to a class of HIV therapies known as viral entry inhibitors that block HIV from entering and infecting healthy cells. In illustrating the importance of CCR5 in HIV, individuals that lack CCR5 expression due to a natural genetic mutation are naturally resistant to HIV infection. Today, six people have been cured of HIV who were given transplanted cells either completely or partially deficient in the CCR5 receptor."

"CytoDyn is currently evaluating the potential role of leronlimab in achieving an HIV cure."

I remain... #BULLISH
https://www.youtube.com/watch?v=IY2j_GPIqRA

*Disclaimer regarding the above speculative opinion post; I only have access to the same exact publicly available information as everyone else and am simply trying to connect some dots. None of the above should be taken as investment advice.